Powered by lexis nexis

Boehringer announces encouraging results from non-valvular atrial fibrillation analysis

Feb 24, 2017 - Marketline Newswire

Boehringer Ingelheim Pharmaceuticals, Inc. has announced encouraging results from a real-world analysis showing that Pradaxa (dabigatran etexilate mesylate) was associated with an improvement in safety and efficacy outcomes compared to warfarin in patients with non-valvular atrial fibrillation (NVAF).

The results were presented at the International Stroke Conference. The study analyzed 7,245 PRADAXA and 14,490 warfarin patients with NVAF who had no prior use of an oral anticoagulant (OAC),...